World-Renowned Aging Researcher and Biomedical
Gerontologist to Lead AgeX’s Research
AgeX Therapeutics (“AgeX”), a subsidiary of BioTime,
Inc. (NYSE MKT:BTX) with a focus on developing new therapies
in the field of biomedical gerontology, today announced the
appointment of distinguished researcher and advocate Aubrey de
Grey, Ph.D. as Vice-President of New Technology Discovery.
“One of the world’s foremost researchers in the science of
aging, and a tireless advocate for such research, Aubrey will be a
strong addition to AgeX as the Company is positioned to emerge as a
leader in the field of biomedical gerontology,” commented Michael
D. West, Ph.D., co-CEO of BioTime. “He has already moved the field
forward to a considerable degree and will help accelerate our
research and development programs.”
A biomedical gerontologist, Dr. de Grey is Co-Founder and Chief
Science Officer of SENS Research Foundation, a 501(c)(3) public
charity dedicated to researching, developing and promoting
comprehensive regenerative medicine solutions for the diseases of
aging. He will continue in his current capacity at SENS Research
and his role at AgeX will be part-time. He is also editor-in-chief
of the bimonthly academic journal Rejuvenation Research, from Mary
Ann Liebert publishers. He has authored the books Ending Aging: The
Rejuvenation Breakthroughs That Could Reverse Human Aging in Our
Lifetime (co-author, 2008, St. Martin’s Griffin) and The
Mitochondrial Free Radical Theory of Aging (1999, R.J Landes) as
well as numerous articles in peer-reviewed scientific journals. He
is a Fellow of the Gerontological Society of America and the
American Aging Association, and sits on the editorial and
scientific advisory boards of many journals and organizations. He
has been interviewed by a variety of top-tier media outlets,
including CBS’ “60 Minutes,” the New York Times, FORTUNE, the
Washington Post, TIME, and “The Colbert Report,” among many others.
He received his B.A. and Ph.D. from the University of Cambridge, in
Cambridge, England.
“The opportunity to help Mike West shape AgeX is a huge next
step in my vision of how to hasten the defeat of aging,” said Dr.
de Grey. “In creating a rejuvenation biotechnology industry, it is
critically important to engage new companies and investors in this
work. I am delighted to be involved in the work of a private
company like AgeX to make this happen.”
“Attracting Dr. de Grey to AgeX represents a significant
milestone in the company’s development and further enhances AgeX’s
emerging leadership,” stated Adi Mohanty, co-CEO of BioTime.
“Additionally, Dr. de Grey’s appointment allows BioTime to better
focus on its three core segments of ophthalmology, aesthetics and
cell and drug delivery.”
About AgeX Therapeutics
AgeX Therapeutics, a subsidiary of BioTime, Inc. (NYSE MKT:BTX),
is a biotechnology company applying technology relating to cell
immortality and regenerative biology, to aging and age-related
diseases. The company has three initial areas of product
development: pluripotent stem cell-derived brown adipocytes
(AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue
Regeneration (iTR). Initial planned indications for these products
are Type II diabetes, cardiac ischemia, and cancer respectively. A
discussion with Dr de Grey regarding AgeX can be viewed here:
http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-EventDetails&EventId=5259612
About BioTime
BioTime is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. Our clinical programs are based on two platform
technologies: pluripotent cells and cell/drug delivery. The
foundation of our core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell
types in the human body. The foundation of our cell delivery
platform is its HyStem® cell and drug delivery matrix technology.
The Company’s current clinical programs are targeting three primary
sectors, aesthetics, ophthalmology and cell/drug delivery. We also
have significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. (“Asterias”) and OncoCyte
Corporation (“OncoCyte”), which we founded and which, until
recently, were our majority-owned consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
About SENS Research Foundation
SENS Research Foundation is a 501(c)(3) nonprofit that works to
research, develop, and promote comprehensive regenerative medicine
solutions for the diseases of aging. SRF is focused on a damage
repair paradigm for treating the diseases of aging, which it
advances through scientific research, advocacy, and education. SENS
Research Foundation supports research projects at universities and
institutes around the world with the goal of curing such
age-related diseases as macular degeneration, heart disease,
cancer, and Alzheimer’s disease. Educating the public and training
researchers to support a growing regenerative medicine field are
also major endeavors of the organization that are being
accomplished though advocacy campaigns and educational programs.
For more information, visit www.sens.org.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements pertaining to
future financial and/or operating results, future growth in
research, technology, clinical development, and potential
opportunities for BioTime, Inc. and its subsidiaries, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates” should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime,
Inc. and its subsidiaries, particularly those mentioned in the
cautionary statements found in more detail in the “Risk Factors”
section of its Annual Reports on Form 10-K and Quarterly Reports on
Form 10-Q filed with the SEC (copies of which may be obtained at
www.sec.gov). Subsequent events and developments may cause these
forward-looking statements to change. BioTime specifically
disclaims any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170713005292/en/
Investor Contact:EVC Group, Inc.Michael Polyviou,
646-445-4800mpolyviou@evcgroup.comorMedia Contact for
AgeX:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.comorMedia Contact for BioTime:JQA
Partners, Inc.Jules Abraham,
917-885-7378jabraham@jqapartners.comorMedia Contact for SENS
Research FoundationJerri Barrett,
408-204-7229Jerri.barrett@sens.org
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024